India Pharma Outlook Team | Tuesday, 13 January 2026
Novartis will build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, part of its $23 billion US investment program announced in April 2025.
The 35,000-square-foot, purpose-built site is expected to come online by 2029, expanding the company’s specialized RLT supply chain and bringing treatments closer to patients in the southeast US.
The facility will help maintain Novartis’ performance of administering more than 99% of doses on the planned day, crucial for RLT, where each dose is individually prepared and delivery is highly time sensitive.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
“Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients,” said Vas Narasimhan, CEO of Novartis. “Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing US manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them.”
RLT combines a tumor-targeting ligand with a therapeutic radioisotope to deliver radiation directly to cancer cells while minimizing damage to healthy tissue. Novartis, the sole company with two FDA-approved RLT treatments, has one of the deepest RLT pipelines, covering prostate, breast, colon, lung, brain, and pancreatic cancers.
Florida’s growing life sciences talent and innovation ecosystem influenced the location. “Novartis’ investment in manufacturing cancer medicines here in Florida—where we’re already no. 2 nationally in both medicine and medical device manufacturing—is an incredible opportunity to welcome world class innovators,” said Florida Secretary of Commerce J. Alex Kelly.
Novartis is also expanding RLT facilities in Indiana, New Jersey, and California, with a fifth US site planned.
.jpg)
.jpg)
